Information Provided By:
Fly News Breaks for June 7, 2019
MRTX
Jun 7, 2019 | 06:08 EDT
Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics to Neutral from Buy. The analyst sees a "less compelling" risk/reward following the recent rally in the shares.
News For MRTX From the Last 2 Days
There are no results for your query MRTX